Non-Muscle Invasive Bladder Urothelial Carcinoma Clinical Trials

6 recruiting

Frequently Asked Questions

Common questions about Non-Muscle Invasive Bladder Urothelial Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 2

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Stage I Bladder Cancer AJCC v8Non-Muscle Invasive Bladder Urothelial CarcinomaRecurrent Non-Muscle Invasive Bladder Urothelial Carcinoma
National Cancer Institute (NCI)160 enrolled113 locationsNCT06770582
Recruiting
Phase 1

IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

Stage 0a Bladder Cancer AJCC v8Stage 0is Bladder Cancer AJCC v8Stage I Bladder Cancer AJCC v8+1 more
University of California, Davis30 enrolled1 locationNCT05843448
Recruiting
Not Applicable

Home-Based Physical Activity Program With Digital App Versus Health Education Group for Improving Physical Activity Among Patients With Non-muscle Invasive Bladder Cancer, The EMPOWER Trial

Localized Non-Muscle Invasive Bladder Urothelial CarcinomaStage 0a Bladder Cancer AJCC v8Stage 0is Bladder Cancer AJCC v8+1 more
University of Washington100 enrolled1 locationNCT07302230
Recruiting
Phase 2

A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer

Non Muscle Invasive Bladder CancerNon-Muscle Invasive Bladder Urothelial Carcinoma
John Sfakianos60 enrolled3 locationsNCT06503614
Recruiting
Phase 4

Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs)

Non Muscle Invasive Bladder CancerHigh Risk Non-Muscle Invasive Bladder Urothelial CarcinomaNon-Muscle Invasive Bladder Urothelial Carcinoma
University of Roma La Sapienza327 enrolled1 locationNCT05962541
Recruiting
Phase 1

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

Urothelial Carcinoma BladderNon Muscle Invasive Bladder CancerNMIBC+4 more
Aura Biosciences55 enrolled17 locationsNCT05483868
Recruiting

Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)

Urothelial CarcinomaMuscle Invasive Bladder Urothelial CarcinomaNon-Muscle Invasive Bladder Urothelial Carcinoma
Fox Chase Cancer Center92 enrolled2 locationsNCT06396533
Recruiting

Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK.

Bladder CancerBladder NeoplasmNon Muscle Invasive Bladder Cancer+8 more
IRCCS San Raffaele20,000 enrolled1 locationNCT06167356